Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov;36(6):436-447.
doi: 10.1016/j.semnephrol.2016.08.001.

Developing Treatments for Chronic Kidney Disease in the 21st Century

Matthew D Breyer  1 , Katalin Susztak  2
Affiliations
Review

Developing Treatments for Chronic Kidney Disease in the 21st Century

Matthew D Breyer et al. Semin Nephrol. 2016 Nov.

Abstract

Chronic kidney disease (CKD) is a lethal and rapidly increasing burden on society. Despite this, there are relatively few therapies in development for the treatment of CKD. Several recent costly phase 3 trials have failed to provide improved renal outcomes, diminishing interest in pharmaceutical investment. Furthermore, poor patient, physician, and payer awareness of CKD as a diagnosis has contributed to slow trial enrollment and successful implementation of these trials. Nevertheless, several therapeutics remain in development for the treatment of CKD, including mineralocorticoid-receptor antagonists, sodium/glucose cotransporter 2 inhibitors, anti-inflammatory drugs, and drugs that mitigate oxidative injury. Success of future CKD therapeutic trials will depend not only on improved understanding of disease pathogenesis, but also on improved trial enrollment rates, through increasing awareness of this disease by the public, policy makers, and the greater medical community.

Keywords: Angiotensin; Diabetic nephropathy; SGTL2; inflammation; renal outcomes.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure and conflict of interest statements: none.

Figures

Figure 1
Figure 1
Please provide.
See this image and copyright information in PMC

References

    1. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2016;67:A7–A8. - PMC - PubMed
    1. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2016;67:A4. - PMC - PubMed
    1. O’Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol. 2015;10:1170–1178. - PMC - PubMed
    1. Szczech LA, Stewart RC, Su H-L, DeLoskey RJ, Astor BC, Fox CH, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease) PLoS One. 2014;9:e110535. - PMC - PubMed
    1. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88:950–957. - PMC - PubMed

MeSH terms